Theranexus Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Theranexus

Dividende od Theranexus su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Theranexus tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Theranexus su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Theranexus mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Theranexus Aktienanalyse

Шта ради Theranexus?

Theranexus SA is a French biotechnology company founded in Lyon in 2013. The company specializes in the development of drugs for the treatment of neurodegenerative diseases. It is one of the few companies specialized in the synthesis of drug candidates through the combination of molecules. The idea to create Theranexus arose from the collaboration between Mathieu Charveriat and Franck Mouthon, two experienced researchers who both worked at the CNRS laboratory at the University of Lyon. Their goal was to synthesize a new class of molecules that are more effective in the treatment of neuropsychiatric disorders such as depression, anxiety, narcolepsy, and Alzheimer's. The company specializes in two main areas: the development of novel drugs and the identification of drug candidates through the modulation of molecules that influence neuronal communication. Theranexus closely collaborates with academic partners to develop a wide range of therapeutic options for neurodegenerative diseases. The company focuses on the development of drugs that work in a unique and seamless way. Theranexus SA has a unique business model in the field of drug development. The company utilizes its innovative technology platform to combine and rearticulate molecules that can influence neuronal communication. The company aims to expand its technology platform and extend its research to other disease areas. The company operates two main activities: the development of drug candidates for the treatment of neurodegenerative diseases and the identification of new drug candidates through the modulation of molecules that influence neuronal communication. The company has recently developed a cathepsin S platform that focuses on the discovery of drugs and drug candidates for the treatment of neurodegenerative diseases. Cathepsin S is an enzyme involved in the formation of amyloid deposits that can play a role in Alzheimer's disease and other neurodegenerative diseases. Theranexus has also developed a platform for the formation of nanoparticles to enable drugs to have a longer half-life and reduce dosage. The company utilizes the platform to stabilize therapeutic molecules by modifying their chemical properties in the body. Theranexus's current products include ANX-368, a drug candidate for the treatment of narcolepsy, and THN102, a combination drug for the treatment of Parkinson's and sleep disorders. The drug candidate TNX-102 is being developed as a potential medication for the treatment of neuropathic pain. Overall, Theranexus SA aims to develop effective and innovative drugs for the treatment of neurodegenerative diseases. The company is committed to expanding its technology platform and continuing its research in other disease areas. Theranexus je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Theranexus akciji

Kolika je dividenda koju isplaćuje Theranexus?

U poslednjih 12 meseci, Theranexus je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Theranexus će verovatno isplatiti dividendu od 0 EUR.

Kolika je dividendna prinosa za Theranexus?

Dividendski prinos od Theranexus trenutno iznosi .

Kada Theranexus isplaćuje dividendu?

Theranexus isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Theranexus?

Theranexus je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Theranexus?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 EUR. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Theranexus?

Theranexus se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Theranexus kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Theranexus od 18. 11. 2024. u iznosu od 0 EUR, morali ste da imate akciju u depou pre Ex-dana 18. 11. 2024..

Kada je Theranexus poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 18. 11. 2024..

Kolika je bila dividenda od Theranexus u godini 2023?

U godini 2023 kompanija Theranexus je isplatila 0 EUR kao dividende.

U kojoj valuti Theranexus isplaćuje dividendu?

Dividende od Theranexus se isplaćuju u EUR.